| Value | ₹7,816 Cr |
|---|---|
| Execution period | 5 years and 1 day (26 Oct 2026 to 27 Oct 2031) |
BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,757.50
- Market cap
- ₹4,21,683 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 34.9×Sector 46.1×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Business Update
Sun Pharma's drug UNLOXCYT received Category 2A preferred designation in updated NCCN guidelines for treating locally advanced cutaneous squamous cell carcinoma.
Sun Pharmaceutical Industries Other Announcement
Sun Pharmaceutical Industries submitted the quarterly confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, as received from their RTA.
Sun Pharmaceutical Industries Credit Rating
Sun Pharma received credit ratings from CRISIL and ICRA for its proposed NCD programme and reaffirmed existing facility ratings.
Sun Pharmaceutical Industries Management Change
Sun Pharmaceutical Industries announced the resignation of Independent Director Gautam Doshi due to personal reasons.
Sun Pharmaceutical Industries Debt & Borrowing: ₹10,000 Cr
Sun Pharma's board approved issuing unsecured Non-Convertible Debentures up to ₹10,000 Crore. Additionally, Independent Director Mr. Gautam Doshi resigned from the company's board.
- Value
- ₹10,000 Cr
Sun Pharmaceutical Industries Board Meeting Date
Sun Pharmaceutical Industries Limited will hold a board meeting on October 12, 2026, to consider a proposed debt issue for fund raising.
Other debt & borrowing announcements
All →Fusion CX Debt & Borrowing: ₹21.85 Cr
Fusion CX lent up to Rs.21.85 Crore (USD 2.3 million) to wholly owned subsidiary Fusion BPO Services. Terms: 8.5% interest, three-year tenure, unsecured.
- Value
- ₹21.85 Cr
- Execution
- 3 years from the date of disbursal
Fusion CX Debt & Borrowing
Fusion CX Limited executed an unsecured inter-corporate term loan at 8.5% p.a. for three years with its wholly owned subsidiary Fusion BPO Services Ltd, a related party. Amount is not stated in the filing.
- Execution
- 3 years from the date of disbursal
Spandana Sphoorty Financial Debt & Borrowing: ₹0.49 Cr
Spandana paid ₹0.49 Crore of quarterly interest on its secured NCDs on 27 October 2026. The coupon rate is 10.75% on a ₹50 Crore issue.
- Value
- ₹0.49 Cr
Mangalam Worldwide Debt & Borrowing: ₹1.14 Cr
Mangalam Worldwide paid Rs. 1.14 Crore interest on its NCDs (ISIN INE0JYY07026) on 28 October 2026, net of TDS. The company confirmed timely payment under Regulation 57.
- Value
- ₹1.14 Cr
Lloyds Metals & Energy Debt & Borrowing: ₹12,370 Cr
Lloyds Metals allotted 1,300 debt securities worth about ₹12,370 Crore on 29 October 2026. Three-year coupon is SOFR plus 450 bps, secured by Virtus Lloyds share pledges.
- Value
- ₹12,370 Cr
- Execution
- 3 years
Lloyds Metals & Energy Debt & Borrowing: ₹1,235 Cr
Lloyds Metals' committee approved terms for USD 130 million senior secured notes, about Rs.1,235 Crore. The notes mature in October 2029 at SOFR plus 450 bps.
- Value
- ₹1,235 Cr